The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 62.50
High: 62.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda and Dignity Health launch OncoVerse platform

29 Feb 2016 07:00

RNS Number : 3883Q
NetScientific PLC
29 February 2016
 

NetScientific plc

 

Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform - OncoVerse™

London, UK - 29 February 2016 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of the US's biggest hospital groups, Dignity Health, to launch OncoVerse, a digital health oncology care platform.

OncoVerse is a software platform designed to enable a patient's care team to collaborate in real-time, allowing clinicians across all disciplines to work together to determine the most effective treatment plan for cancer patients. Dignity Health engaged Wanda to develop the software due to the Company's proven track record in developing effective platforms that support informed treatment decisions. The software will also help to reduce administrative costs associated with high quality cancer care.

 

Dignity Health is a network of nearly 9,000 physicians and more than 400 care centers, including hospitals and primary care clinics spanning 21 US states. The OncoVerse platform will support Dignity Health's physicians and healthcare professionals to enable them to make informed decisions on the treatment of cancer patients. It will also enable Dignity Health to expand the geographic reach of its clinical decision-making support system to reach the most rural and remote areas - allowing all patients to benefit from insights previously only shared at large medical centers.

 

Wanda and Dignity Health are shareholders in Oncoverse LLC, a San Francisco based digital health company, and the creator of the OncoVerseTM software platform. Wanda and Dignity Health will jointly market the Oncoverse platform to other oncology programs across the US later in 2016 to earn revenues through uptake of the platform. The relationship with Dignity Health will also allow for cross-marketing of existing and future Wanda products.

 

Facilitating individualized cancer decision support is becoming increasingly important as cancer therapies advance. Wanda's core technology aims to improve the efficiency and effectiveness of the management of chronic conditions.

 

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "Wanda is the Group's lead subsidiary in our digital health franchise. The launch of Oncoverse with Dignity Health, and its huge US network, is a significant milestone for the Company and further endorses its core technology. This deal marks the second partnership that Wanda has secured with a leading US healthcare group since the start of 2016 as it continues to develop more platforms to better manage chronic conditions."

 

 

-ends-

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

 

About OncoVerse

San Francisco-based Oncoverse, LLC is a digital health care platform company which enables health care professionals to collaborate on cancer patient care decisions, and to monitor the progress of patient therapies. OncoverseTM has the potential to transform cancer care delivery by establishing a common platform for all cancer patients to access the best medical expertise, while at the same time providing physicians with an opportunity to present their oncology cases for evidence-based peer collaboration, review, treatment recommendations and second opinions that are available 24/7 from any computer or other web-enabled device.

 

About Dignity Health

Dignity Health, one of the nation's largest health care systems, is a 21-state network of nearly 9,000 physicians, 59,000 employees, and more than 400 care centers, including hospitals, urgent and occupational care, imaging centers, home health, and primary care clinics. Headquartered in San Francisco, Dignity Health is dedicated to providing compassionate, high-quality and affordable patient-centered care with special attention to the poor and underserved. In FY15, Dignity Health provided $1.7 billion in charitable care and services. For more information, please visit our website at www.dignityhealth.org. You can also follow us on Twitter and Facebook.

 

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific company. More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRZMGZZMRNGVZZ
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.